Your session is about to expire
← Back to Search
Anti-OX40 Agonist Monoclonal Antibody PF-04518600 for Acute Myelogenous Leukemia
Study Summary
This trial is testing a combination of drugs to treat patients with acute myeloid leukemia that has come back or does not respond to treatment. The drugs will be given to see if they help the body's immune system attack the cancer, and if they stop the growth of tumor cells.
- Acute Myelogenous Leukemia
- Acute Myeloid Leukemia
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 1 & 2 trial • 50 Patients • NCT03390296Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What are the primary benefits of Anti-OX40 Agonist Monoclonal Antibody PF-04518600?
"Anti-OX40 Agonist Monoclonal Antibody PF-04518600 is a medication that oncologists often prescribe to treat malignant neoplasms. This drug can also help patients with comorbidity, neutropenia and/or thrombocytopenia, and anemia."
Are there any other drugs that have been tested in a similar way to Anti-OX40 Agonist Monoclonal Antibody PF-04518600?
"There are a total of 493 ongoing clinical trials for Anti-OX40 Agonist Monoclonal Antibody PF-04518600, with 69 of those in Phase 3. While some of the Alberta-based trials for this medication are close to being full, there are 15399 other locations across the world running clinical trials."
How many people will be participating in this study at its peak?
"Unfortunately, this particular trial is no longer looking for patients. Although, it was last updated on September 22nd, 2022. There are currently 1522 trials actively recruiting patients with leukemia and 493 trials for Anti-OX40 Agonist Monoclonal Antibody PF-04518600 that are admitting patients."
Are we still enrolling participants for this clinical trial?
"Unfortunately, this particular trial is not currently looking for new participants. Although the study was originally posted on December 27th, 2017, recruitment has since closed. However, there are over 2 thousand other trials that are still recruiting patients right now."
Share this study with friends
Copy Link
Messenger